• Global biomanufacturing leader 21st.BIO announced today that it is now granting access to its precision fermentation technology platform to food and ingredient manufacturers, enabling sustainable production of dairy proteins at a cost competitive.

  • Access to 21st.BIO’s technology represents a step change in food production with precision fermentation, allowing manufacturers to focus on production, product development and marketing.

  • 21st.BIO offers the most advanced production strains, the best final product quality, exclusive know-how and considerable savings in time and resources for manufacturers.

  • This announcement follows 21st.BIO’s successful increase in beta-lactoglobulin production.

Copenhagen, Denmark And DAVIS, California., January 31, 2024 /PRNewswire/ — 21st.BIO, a global leader in biomanufacturing, today announced that it is granting access to its precision fermentation technology platform to ingredient manufacturers enabling the production of dairy proteins at a competitive cost . This follows 21st.BIO’s successful scale-up of beta-lactoglobulin protein, a major milk protein that provides high-value nutritional and textural components to milk and other dairy ingredients.

By widely offering its precision fermentation technology platform, 21st.BIO mitigates the costs and time associated with development, opening access to proven industrial-scale production technology for the precision fermentation of alternative proteins. The platform offers a sustainable, less carbon and resource-intensive alternative to traditional livestock production methods and helps stabilize global food supply chains. According to recent studies, protein production through precision fermentation reduces greenhouse gas (GHG) emissions and land and water use by 90-96% compared to original production. animal.

With the 21st.BIO platform, customers have access to world-leading industrial production strains and fermentation processes, as well as assistance with scaling, technology transfers to contract manufacturers and regulatory approvals for faster, lower cost time to market. 21st.BIO continuously optimizes strains and processes, ensuring customers are always one step ahead of the market.

21st.BIO has the industry’s most advanced precision fermentation technology platform for large-scale production. The technological base is licensed from Novozymes, which has 40 years of experience in perfecting strains and production processes for industrial production. The technology base is already used to deliver dozens of food grade products to the market today.

21st.BIO’s technology can be optimized for each customer’s specific goals, such as nutritional enrichment of a plant-based product, texture improvement of alternative dairy products, and medical nutrition.

21st.BIO’s customers can be innovative start-ups planning to commercialize one or more proteins, as well as established players expanding into sustainable alternatives, and dairy companies looking to expand with the growing global demand for protein while reducing their mark on the market. the environment.

Thomas SchmidtCEO of 21st.BIO said: “We founded 21st.BIO with a simple mission: to make precision fermentation technology accessible to as many companies as possible, so that they can successfully bring their product to market at a competitive price. We believe this is the best way for technology to support and accelerate the transition to more sustainable, higher-quality nutrition globally. With this new offering, I am proud that companies will be able to safely scale the innovation to industrial production and meeting global demand using our technology and expertise.

With a technology platform based on Novonesis (formerly Novozymes) and funding from Novo Holdings, 21st.BIO is uniquely positioned to help accelerate the search for greener, more nutritious alternatives in the food industry.


About 21st.BIO
21st.BIO was founded with a simple mission: to make industrial-scale precision fermentation technology accessible to as many people as possible, so that companies can successfully commercialize their biotechnology innovations at a competitive price. The company’s founders found that too often, major biological innovations and molecules fail to translate into commercial success. The innovation is ready, the market is there, but production costs remain too high for the product to be widespread. Industry insiders call it the “valley of death,” and that’s exactly what 21st.BIO aims to fill.

Founded in 2020, 21st.BIO is headquartered in Copenhagen, Denmarkand has a world-class R&D team as well as laboratories in both Copenhagen, Denmark And Davis, California. With a mission to help bio-industrial companies around the world move from molecular innovation to large-scale production, 21st.BIO enables its clients to meet market demands and thus advance the green transition to worldwide. 21st.BIO focuses on the development of technologies for the industrial production of proteins and other molecules of interest to the food, materials and agricultural industries. Established as a fully integrated end-to-end partner, 21st.BIO supports clients from technical assessment, strain development and optimization, production processes and scale-up, technology transfer to ‘to large-scale manufacturing and regulatory services.

21st.BIO’s fermentation technology is partly licensed from Novonesis (formerly Novozymes), which developed its platform over several decades.

Visit our website: https://21st.bio/ | Tag us on LinkedIn: 21st.BIO

Press contact:
Mathilde Pinon
Marketing and Business Development Manager
Email: m.pinon@21st.bio

The following files are available for download:



View original content: https://www.prnewswire.co.uk/news-releases/21stbio-opens-a-more-sustainable-avenue-for-industrial-scale-dairy-protein-production-302048991.html

Leave a Reply